CELG News and Press, Celgene Corporation From 11/25/19

Merger activity decreased, with three new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Carolina Financial Corporation (CARO) by United Bankshares (UBSI) for $1.1 billion in an all-stock deal. Under the terms of the agreement, United will...

Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...

Stocks have rallied sharply higher since the early October lows because of perceived progress on China trade talks and dovish Federal Reserve policy. However, that doesn't necessarily mean every stock is worth buying today. A trade deal could still get derailed, and the Fed many not provide fu...

A total of $18.5B of Celgene (NASDAQ: CELG ) notes have been validly tendered under Bristol-Myers Squibb's (NYSE: BMY ) exchange offer for the notes. More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Read more ...

GSK Facing Headwinds in Established Products but Balanced by Growth Opportunities in Oncology GlaxoSmithKline ( GSK ) faces several headwinds in its business, with Advair facing generic pressure and its new two-drug HIV regimen struggling to gain traction. On the latter point, the company mu...

THOUSAND OAKS, Calif. , Nov. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla ® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthr...

Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s contingent value rights (NASDAQ: CELGZ) (“Celg...

This article was first published on October 20, 2019. Tekla Healthcare Investors ( HQH ) has been lagging the broader market, along with the rest of the healthcare sector as a whole. The continued rhetoric from presidential hopefuls and even the current White House administration has reall...

As the merger between Bristol-Myers Squibb ( BMY ) and Celgene ( CELG ) approaches the finish line, investors face the surprising dilemma of how to handle Celgene trading at $110 as the merger is a day away from closing. Along with my previous recommendation , investors want to own BMY af...

NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO) will replace Celgene Corp. (NASD: CELG) in the S&P 100, and ServiceNow Inc. (NYSE: NOW) will replace Celgene in the S&P 500 prior to the open of trading on Thursday, November 21.  Bristol-Myers ...